C4X Discovery Holdings appoints two to board
In addition, Mr. Hoy has been appointed permanent CFO following a period as interim CFO.
Mr. Hoy has more than 20 years' experience in the pharmaceutical and biotechnology industries and has held a number of senior financial and general management positions in both the UK and U.S.
Previously, Mr. Hoy was Chief Financial Officer of Plethora Solutions Holdings plc, an AIM-listed specialty pharmaceutical company, Chief Executive Officer of Xcellsyz Limited, a UK venture capital-backed life science company, and Senior Director of Geron Corporation's stem-cell focused UK subsidiary.
Mr. Hoy is a co-founder of Seven Hills Venture Partners, a life sciences advisory firm, and currently serves on the Board of Directors for e-Therapeutics plc.
Mr. Fox joined C4X Discovery in September 2015 and is an experienced drug-discovery biologist, having worked on and managed a number of discovery and development projects during the past 18 years from initial target selection through to clinical studies.
Prior to joining C4X Discovery, Mr. Fox was director of Respiratory Research at Pulmagen Therapeutics, a clinical stage company spun out of Argenta in 2010.
Mr. Fox was part of the Etiologics Team that merged with Argenta Discovery in 2004 and, prior to that, he worked for Bayer as a Research Scientist. ■
LATEST MOVES FROM United Kingdom
- John Lewis Partnership appoints Laura Wade-Gery as director
- 40% of senior executives to leave Reckitt Benckiser
- Oxford Immunotec Global appoints Stefan Linn as COO
- Terra Firma Capital appoints Jerry Patava to board
- Willis Towers Watson announces Michael J. Burwell as CFO
More inside POST
COO, a chameleon in the company Leadership